Table 3.
Promising COVID-19 viral vector-based vaccine candidates in clinical development.
| Type | Manufacturer | Name | Phase | RoA | Trial Registration |
|---|---|---|---|---|---|
| VVnra | AstraZeneca + University of Oxford | ChAdOx1-S (Covishield) | Approved (UK, India, Argentina, México) | IM | NCT04760132 |
| VVnra | CanSino Biological | Recombinant coronavirus vaccine (Ad5 vector) | EUA (Mexico) | IM | NCT04526990 |
| VVnra | Gamaleya Research Institute | Gam-COVID-Vac | EUA (Russia, Argentina, Bolivia, UAE) | IM | NCT04530396 |
| VVnra | Janssen Pharmaceutical | Ad26.COV2. S | EUA (US, Canada) | IM | NCT04505722 |
| VVrb | Beijing Wantai Biological Pharmacy | DelNS1-2019-nCoV-RBD-OPT1 | Phase 2 | IN | ChiCTR2000039715 |
| VVrb | Israel Institute for Biological Research | rVSV-SARS-CoV-2-S Vaccine | Phase 1/2 | IM | NCT04608305 |
VVnra: Viral vector non-replicating; VVrb: Viral vector replicating RoA, route of administration; IM, Intramuscular; IN, Intranasal.